LONDON (Alliance News) - 4D Pharma PLC said on Tuesday its product Blautix showed a positive response after its first clinical trial.
The product, for treatment of the symptoms of irritable bowel syndrome, proved to be "safe and well tolerated" throughout the trial. Patients given Blautix showed a greater response over those given a placebo, and the majority of those given Blautix reported an overall improvement in IBS symptoms.
The company said the findings of this first clinical trial were "encouraging" and will enable Blautix to progress into larger clinical studies for further evaluation as a potential treatment for IBS.
"Whilst the primary rationale for the trial was safety and tolerability, and recognising that it is a phase 1 trial in a very limited number of subjects, the data trends towards the overall effectiveness of Blautix. This gives us confidence to progress to the next phase towards approval of a safe, effective treatment in IBS," said Duncan Peyton, chief executive of 4D Pharma.
Shares in 4D Pharma were down 2.9% Tuesday morning at 760.00 pence.
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2016 Alliance News Limited. All Rights Reserved.
